Cargando…
Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
Clozapine is considered « the golden standard » for the management of treatment-resistant schizophrenia, but many patients do not present adequate responsivity even to this antipsychotic. If we add the need to strictly monitor the hematologic and cardiometabolic adverse events during each clozapine...
Autor principal: | Vasiliu, Octavian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744942/ https://www.ncbi.nlm.nih.gov/pubmed/36523870 http://dx.doi.org/10.3389/fpsyt.2022.1069432 |
Ejemplares similares
-
The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders
por: Vasiliu, Octavian
Publicado: (2023) -
Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021) -
Current Status of Evidence for a New Diagnosis: Food Addiction-A Literature Review
por: Vasiliu, Octavian
Publicado: (2022) -
Therapeutic management of buying/shopping disorder: A systematic literature review and evidence-based recommendations
por: Vasiliu, Octavian
Publicado: (2022) -
Methylation Analysis in Monozygotic Twins With Treatment-Resistant Schizophrenia and Discordant Responses to Clozapine
por: Kikuchi, Masataka, et al.
Publicado: (2021)